Spironolactone Use in Heart Failure Treatment
Author Information
Author(s): Lachaine Jean, Beauchemin Catherine, Ramos Elodie
Primary Institution: Faculty of Pharmacy, University of Montreal
Hypothesis
The study aims to estimate the use of spironolactone by patients with heart failure, the incidence of key adverse events, and patient compliance.
Conclusion
Use of spironolactone is associated with an incidence of adverse events, which may have an impact on treatment compliance.
Supporting Evidence
- 15.1% of heart failure patients used spironolactone.
- The incidence of hyperkalemia was 3.3% in spironolactone users compared to 1.4% in non-users.
- Treatment compliance with spironolactone was 45.6%, lower than with ACE inhibitors and beta-blockers.
Takeaway
Spironolactone can help heart failure patients, but many people stop taking it because of side effects like high potassium and breast swelling.
Methodology
Data from the Quebec provincial medical and drug plans were analyzed for patients diagnosed with heart failure to estimate spironolactone use, adverse events, and treatment compliance.
Potential Biases
Potential overestimation of treatment adherence due to reliance on reimbursed medications and limitations in coding practices.
Limitations
The study relies on administrative data, which may not accurately reflect actual medication adherence and may underestimate the incidence of adverse events.
Participant Demographics
The study included 82,018 heart failure patients, with a higher proportion of men among spironolactone users.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website